M&A / Deals Beeline raises $300m for BMS drugs, and other biofinancings PharmaphorumBeeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week.M&A / DealsRead full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaphorum Beeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week. M&A / DealsRead full story Post navigation Previous: Most patients “won’t see benefit” with Alzheimer’s drugsNext: Revolution doubles stock offering target to $2B following pancreatic cancer win Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026